Clinical Trials Logo

Richter's Transformation clinical trials

View clinical trials related to Richter's Transformation.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03778073 Terminated - Clinical trials for B-cell Non Hodgkin Lymphoma

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Start date: April 17, 2019
Phase: Phase 1
Study type: Interventional

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

NCT ID: NCT03153514 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

CLLTX1
Start date: November 13, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the feasibility, efficacy and safety of an obinutuzumab containing conditioning regimen for poor risk CLL patients and patients with Richter's transformation requiring an allogeneic stem cell transplantation.

NCT ID: NCT03121534 Terminated - Clinical trials for Hematopoietic/Lymphoid Cancer

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Start date: June 22, 2017
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if blinatumomab can help to control Richter Transformation (RT, a type of blood cancer). The safety of this drug will also be studied. This is an investigational study. Blinatumomab is FDA approved and commercially available for the treatment of acute lymphoblastic leukemia (ALL). It is investigational to use blinatumomab to treat patients with RT. The study doctor can explain how the study drug is designed to work. Up to 21 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT02378038 Terminated - Clinical trials for Richter's Transformation

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with Richter's Transformation.

NCT ID: NCT02138786 Terminated - Clinical trials for Richter's Transformation

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

SIRRT
Start date: November 14, 2014
Phase: Phase 2
Study type: Interventional

This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one chemo-immunotherapy regimen for CLL.